Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shinogi

- PMLiVE

GSK and XenoPort end restless legs syndrome collaboration

Follows tough approval period for Horizant and subsequent poor sales 

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

- PMLiVE

Pfizer helps fund biotech venture from former researchers at closed Kent facility

Ziarco headed by former Pfizer chief scientific officer, allergy and respiratory research, Mike Yeadon

- PMLiVE

Gilead advances HIV drug into phase III

The treatment is a chemical variant of Gilead's successful HIV drug Viread

- PMLiVE

GSK sales drop as austerity measures hit business in Europe

Revenues in region drop 9 per cent

- PMLiVE

GSK takes severe asthma antibody into phase III

Mepolizumab could help patients who cannot prevent attacks using current therapies

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

- PMLiVE

Sir Christopher Gent ‘stepping down’ as GSK chair

He will leave the pharma firm in the next two or three years, according to a UK press report

- PMLiVE

GSK, Pfizer and Shionogi rewrite HIV joint venture terms

Comes ahead of first regulatory submissions for lead drug candidate dolutegravir

- PMLiVE

Pfizer’s Elvira Sanz named next president of Farmaindustria

Will lead Spanish pharma industry body for the new two years

- PMLiVE

The first public presentation of human Lipitor data

This month In 1994: The first public presentation of human Lipitor data

- PMLiVE

Pfizer pays $680m to buy ADHD drug developer NextWave

Portfolio includes once-daily Quillivant XR

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links